ArticleInternational journal of retina and vitreous2025
Retinoblastoma survival trend: a 30-year analysis from a referral single center in Iran.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global, regional, and national burden and changing trends of hepatoblastoma and retinoblastoma from 1990 to 2021, and projections until 2050: findings from the Global Burden of Disease Study 2021.Translational pediatrics · 2026Article
- Smartphone applications for early screening of retinoblastoma: a scoping review.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of retinoblastoma (Rb) has undergone significant improvements over the last century. This study aims to assess the trend of enucleation and mortality in retinoblastoma patients during the last 3 decades.
methodsThe study utilized data from the referral center for ocular oncology in Rasool Akram Hospital, Tehran, Iran. It included all patients diagnosed with Rb from August 1991 to December 2018. The study investigated the trend of enucleation and mortality during three-time intervals: before 2001 (T1), during 2001-2007 (T2), and 2008-2018 (T3). Additionally, it assessed the trend of enucleation and mortality based on laterality, age and presentation of Rb (strabismus and leukocoria).
resultsThe incidence of enucleation decreased significantly from T1 to T3 (74-41%) during the study period (p-value < 0.001). Pairwise comparisons between T1 and T3 revealed a significant decrease in the incidence of enucleation (74% vs. 41%, p-value < 0.001). The study also demonstrated a significant reduction in the incidence of enucleation when comparing T2 to T3 (60% vs. 41%, p-value < 0.001). Comparing time intervals, there was no significant difference between T2 and T3 regarding the incidence of death (4% vs. 1%), but both intervals had statistically significant lower death rates compared with T1 (26%, both p-values < 0.001).
conclusionThis study revealed that Introduction of systemic chemotherapy as mainstay of Rb treatment, has led to a significant reduction in mortality and morbidity rates. The incorporation of targeted chemotherapy has further decreased the need for enucleation, but it has not substantially impacted the mortality rate. Unfortunately, in spite of reduction trend in enucleation, systemic and targeted chemotherapy was unable to save the affected globe in nearly half of the patients, even when the malignancy was diagnosed in the earlier stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.